Allergan Reports the Acceptance of EMA’s MAA for Abicipar to Treat Neovascular Age-Related Macular Degeneration

 Allergan Reports the Acceptance of EMA’s MAA for Abicipar to Treat Neovascular Age-Related Macular Degeneration

Shots:

  • Molecular Partners announces that EMA has validated the MAA of its partner Allergan for Abicipar to treat patients with nAMD
  • Post-approval, Abicipar will be the first anti-VEGF therapy to maintain vision gains with a 12-week dosing interval. The companies collaborated to advance clinical programs in ophthalmology and to robust pipeline of DARPin drug candidates in oncology and immuno-oncology
  • Abicipar pegol is an anti-VEGF therapy based on the Molecular Partners’ DARPin platform and currently being evaluated in P-III study. Additionally, Molecular Partners has terminated its agreement with Amgen for exclusive development & commercialization of MP0310 which is expected to enter into the clinic in H2’19

Click here to­ read full press release/ article | Ref: Molecular Partners | Image: Stat News

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post